ASRS 2023: 2-year data on the PHOTON study of 8 milligrams of aflibercept for diabetic macular oedema (DME)

News
Video

Diana Do, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington, to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

At the 2023 ASRS meeting in Seattle, Washington, Diana Do, MD joined our team to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Diana Do, MD:

Hi, I'm Dr Diana Do, professor of ophthalmology and vice chair of clinical affairs at the Byers Eye Institute at Stanford University. Today, I had the pleasure of delivering the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

The key take home points are that 8 milligrams of aflibercept dosed every 12 weeks or every 16 Weeks was non-inferior to 2 milligrams of aflibercept given every 8 weeks, and these benefits were sustained through 2 years of follow up. In addition, it's remarkable that those eyes randomised to the 8 milligram dosing group were able to maintain dosing intervals of 12 weeks and 16 weeks for the vast majority of patients in the study. In fact, 89 percent of 8 milligram-treated eyes maintained 12 weeks or longer dosing intervals through 2 years. And at the last interval of dosing. Approximately 27 percent of subjects are able to be dosed at 24 weeks. In terms of safety, 8 milligrams of aflibercept had very low rates of intraocular inflammation, and the safety was comparable to that of 2 milligrams of aflibercept. In summary, 8 milligrams of aflibercept provided improved visual acuity outcomes and reductions in retinal thickness that were sustained through 2 years while decreasing the burden of frequent injections.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.